500 lines
No EOL
36 KiB
HTML
500 lines
No EOL
36 KiB
HTML
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
|
|
"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml">
|
|
<head>
|
|
<title>Research Activities, October 1997: Feature Story; Research on Heart Disease; Medical Effectiveness/Outcomes Research</title>
|
|
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" />
|
|
|
|
<!-- "metadata" -->
|
|
<meta name="Title" content="Research Activities, October 1997" />
|
|
<meta name="keywords" content="Agency for Health Care Policy and Research, Agency for Healthcare Research and Quality, AHRQ, AHCPR, AIDS/HIV, ambulatory care, benchmark, child, cost, elderly, health cost, healthcare cost, hospital, long-term care, managed care, markets, mental health, methodology, minority health, nursing, nursing homes, outcome research, out-of-pocket spending, patient care, primary, primary care, research, rural, spending, study, Translating Research Into Practice, TRIP" />
|
|
<meta name="description" content="Online newsletter summarizing published findings from AHRQ-funded studies, new AHRQ publications and products, and funding opportunities." />
|
|
<meta name="creator" content="Agency for Healthcare Research and Quality (AHRQ)" />
|
|
<meta name="language" content="English" />
|
|
<!-- end metadata -->
|
|
<link href="/includes/archive.css" rel="stylesheet" type="text/css" />
|
|
<link href="/includes/ahrqstyleprint_arch.css" rel="stylesheet" type="text/css" media="print" />
|
|
<script>
|
|
(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
|
|
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
|
|
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
|
|
})(window,document,'script','//www.google-analytics.com/analytics.js','ga');
|
|
|
|
ga('create', 'UA-75759936-1', 'auto');
|
|
ga(' set', 'anonymizeIp', true);
|
|
|
|
ga('send', 'pageview');
|
|
|
|
</script></head><body><!-- Google Tag Manager -->
|
|
<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-W4DST4"
|
|
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
|
|
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
|
|
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
|
|
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
|
|
'//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
|
|
})(window,document,'script','dataLayer','GTM-W4DST4');</script>
|
|
<!-- End Google Tag Manager -->
|
|
<noscript>
|
|
Your browser doesn't support JavaScript. Please upgrade to a modern browser or enable JavaScript in your existing browser.
|
|
</noscript>
|
|
|
|
<!-- Page Header v2.0 -->
|
|
<a name="top" id="top"></a>
|
|
<!--Begin Banner CodeS-->
|
|
<div id="ahrqbanner">
|
|
<div class="hhsportion">
|
|
<a href="#h1" class="skipnav">Skip Navigation</a>
|
|
<a href="http://www.hhs.gov" title="U.S. Department of Health and Human Services">
|
|
<img src="/images/hhs_banner.gif" alt="U.S. Department of Health and Human Services" />
|
|
</a>
|
|
<a href="http://www.hhs.gov" title="www.hhs.gov" class="hhsright">
|
|
<img src="/images/hhs_link.gif" alt="www.hhs.gov" />
|
|
</a>
|
|
</div>
|
|
|
|
<div class="ahrqportion">
|
|
<a href="/" title="Archive: Agency for Healthcare Research Quality">
|
|
<img src="/images/ahrq_banner.gif" alt="Agency for Healthcare Research Quality" />
|
|
</a><form name="searchForm" method="get" action="https://search.ahrq.gov/search" id="banner_searchform">
|
|
<label for="search" style="z-index:-1;position:relative;margin-right:-65px; font-size:0px;">Search</label>
|
|
<input name="q" type="text" value=" Search Archive" size="11" onfocus="this.value='';" class="gotext" label="Search archive" id="search" />
|
|
<input type="hidden" name="entqr" value="0" />
|
|
<input type="hidden" name="output" value="xml_no_dtd" />
|
|
<input type="hidden" name="proxystylesheet" value="ARCHIVE_Front_End" />
|
|
<input type="hidden" name="client" value="ARCHIVE_Front_End" />
|
|
<input type="hidden" name="site" value="ARCHIVE_AHRQ_GOV" />
|
|
<input src="/images/topbn_GoButton.gif" class="gobtn" name="Submit" onclick="javascript:document.searchForm.submit();" type="image" alt="Search" />
|
|
</form>
|
|
<a href="https://www.ahrq.gov/" class="ahrqright">www.ahrq.gov</a>
|
|
</div><div class="ahrqlinks"><a href="https://www.ahrq.gov/">AHRQ Home—Live Site</a> | <a href="/">Archive Home</a> | <a href="/sitemap.htm">Site Map</a> <!-- | <img src="/images/envelope1.jpg" alt="" width="21" height="14" /><a href="https://subscriptions.ahrq.gov/service/multi_subscribe.html?code=USAHRQ">E-mail Updates</a> --></div>
|
|
</div>
|
|
<div id="PrintBanner">
|
|
<img src="/images/printbanner_arch.jpg" alt="Archive print banner" />
|
|
</div>
|
|
<a name="h1"></a>
|
|
<!-- End banner code -->
|
|
<!-- End of Page header -->
|
|
|
|
<!-- Content Body -->
|
|
<div id="mainContent">
|
|
<table width="100%" border="0" cellspacing="0" cellpadding="0" >
|
|
<tr valign="top">
|
|
<td width="70%">
|
|
<!-- Center Content section -->
|
|
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="margin-left:10px; margin-right:10px;margin-top:5px" summary="This table gives the layout format of the bread crumb area and the center content area.">
|
|
<!--DWLayoutTable-->
|
|
<tr>
|
|
<td class="crumb_link"><div id="crumbContent">
|
|
<p><strong>You Are Here:</strong> <span class="crumb_link"><a href="/" class="crumb_link">AHRQ Archive Home</a> > <a href="/research/resarch.htm" class="crumb_link"><em>Research Activities</em> Archive</a> > <a href="." class="crumb_link">October 1997</a>
|
|
</span></p>
|
|
</div>
|
|
</td>
|
|
</tr>
|
|
<tr>
|
|
<td><h1><a name="h1" id="h1"></a>Feature Story </h1>
|
|
</td>
|
|
</tr>
|
|
<tr>
|
|
<td><div id="centerContent"><div class="headnote">
|
|
<p>This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: <a href="https://info.ahrq.gov/">https://info.ahrq.gov</a>. Let us know the nature of the problem, the Web address of what you want, and your contact information. </p>
|
|
|
|
|
|
<p>Please go to <a href="https://www.ahrq.gov/">www.ahrq.gov</a> for current information.</p></div>
|
|
<a name="head1"></a>
|
|
<a name="head2"></a><h2>New EKG add-on could reduce deaths from heart
|
|
attack</h2>
|
|
<p>Busy emergency room doctors now have a new ally in their fight to save the lives of heart attack
|
|
victims. The ally is a computerized decisionmaking aid that will be built into the standard
|
|
electrocardiograph (EKG) machine to instantly print predictions, based on the patients EKG and
|
|
other clinical information, of whether that individual is likely to benefit from potentially lifesaving
|
|
treatment with thrombolytic (clot-dissolving) drugs.</p><p>
|
|
|
|
The new real-time predictive instrument was developed and tested by a team of researchers whose
|
|
work was supported by the Agency for Health Care Policy and Research (HS06208). The
|
|
description of the instrument and all necessary details to calculate its predictions for any patient
|
|
with a heart attack appeared in the October 1 <em>Annals of Internal Medicine</em>. </p>
|
|
|
|
<p>According to AHCPR's Administrator John M. Eisenberg, M.D., physicians currently base
|
|
thrombolytic therapy decisions mostly on the same kinds of information the instrument uses, but
|
|
with the new tool, the process will be more systematic, precise, and practical.</p><p>
|
|
|
|
Thrombolytic drugs help many patients survive a heart attack if administered in time. However, if
|
|
the drugs are administered too late, or given to patients unlikely to benefit, they are of little or no
|
|
help, may cause serious complications, and waste money. Other than timing (AHCPR-funded and
|
|
other research shows that heart attack victims often delay seeking care), the main reasons more
|
|
patients do not receive thrombolytic therapy is failure to recognize suitable candidates and fear of
|
|
complications.</p>
|
|
|
|
<p>According to the research team leader, Harry P. Selker, M.D., of Boston's New England Medical
|
|
Center, the new instrument estimates the patients' probabilities (from zero to 100 percent) of
|
|
suffering cardiac arrest within 48 hours, of dying within 30 days, or of dying within 1 year, if the
|
|
patient is, or is not, treated with thrombolytic therapy in the emergency room. The instrument also
|
|
calculates the patients' likelihoods of developing serious complications, such as hemorrhagic
|
|
stroke or major bleeding, if given thrombolytic therapy.</p><p>
|
|
|
|
The study involved researchers from New England Medical Center/Tufts University School of
|
|
Medicine, Duke University Medical Center, the University of Washington School of Medicine,
|
|
Boston Universitys Department of Mathematics, Harbor-UCLA Medical Center, and the
|
|
University of Southern California's Department of Medicine.</p>
|
|
|
|
<p>AHCPR is currently funding a followup to Dr. Selker's study—a randomized controlled trial
|
|
in a
|
|
diverse group of 28 hospitals across the country to test the clinical impact of making this
|
|
thrombolytic predictive instrument available in emergency rooms.</p>
|
|
<p>For details of the current study, see "Patient-specific predictions of outcomes in myocardial
|
|
infarction for real-time emergency use: A thrombolytic predictive instrument," by Dr. Selker, John
|
|
L. Griffith, Ph.D., Joni R. Beshansky, R.N., M.P.H., and others, in the October 1, 1997, issue of
|
|
the <em>Annals of Internal Medicine</em>, 127(7), pp. 538-556.</p>
|
|
|
|
<p class="size2"><a href=".">Return to Contents</a></p>
|
|
<a name="head3"></a><h1>Research on Heart Disease</h1>
|
|
<a name="head4"></a><h2>Study reaffirms link between angioplasty outcomes
|
|
and hospital and physician experience</h2>
|
|
<p>In the largest study of its kind to date, researchers have once again found that elderly patients
|
|
undergoing coronary angioplasty are well advised to have the procedure done in hospitals that
|
|
perform 200 or more angioplasties each year and by physicians who perform 75 or more
|
|
angioplasties each year. These patients suffer fewer complications and deaths than similar patients
|
|
who undergo angioplasties at hospitals and by physicians who perform the procedure less often,
|
|
according to the study, which was supported by the Agency for Health Care Policy and Research
|
|
(HS08805 and the Ischemic Heart Disease Patient Outcomes Research Team [PORT],
|
|
HS06503).</p><p>
|
|
|
|
In this study, the rate of followup bypass surgery (a marker for failed angioplasty) and/or death
|
|
was greatest for patients treated by low-volume physicians in low-volume hospitals (4.2 percent
|
|
and 6.9 percent, respectively) and lowest for patients treated by high-volume physicians in
|
|
high-volume hospitals (2.5 percent and 4.5 percent, respectively).</p>
|
|
|
|
<p>The empirical data provided by this study support minimum angioplasty volume standards for
|
|
physicians and hospitals, notes James G. Jollis, M.D., of Duke University Medical Center. Dr.
|
|
Jollis and his colleagues examined in-hospital bypass surgery and death after angioplasty for all
|
|
1992 Medicare enrollees who had angioplasties, according to 1992 physician and hospital
|
|
Medicare procedure volume. They found that more than 50 percent of physicians and 25 percent
|
|
of hospitals performing this procedure in 1992 were unlikely to have met the 1988 American
|
|
College of Cardiology/American Heart Association (ACC/AHA) minimum volume guidelines of
|
|
200 procedures per year for hospitals and 50 procedures per year for surgeons.</p> <p>
|
|
|
|
Improved outcomes were seen up to threshold values of 75 Medicare cases per physician and 200
|
|
Medicare cases per hospital or overall volumes of 150 to 225 cases per physician and 400 to 600
|
|
cases per hospital. It is likely that the increased skill of high-volume operators in successfully dilating lesions and performing "bailing out" procedures after abrupt closure of an
|
|
artery led to the lower rates of followup bypass surgery for these providers. On the other hand,
|
|
referring physicians may have known which angioplasty providers had better outcomes and
|
|
selectively referred more patients to such providers. Thus, these providers performed the highest
|
|
volumes of procedures. In conclusion, Dr. Jollis points out the need for a similar study using more
|
|
contemporary data to assess the impact of stents and platelet inhibitors on outcomes by
|
|
volume.</p>
|
|
|
|
<p>Details are in "Relationship between physician and hospital coronary angioplasty volume and
|
|
outcome in elderly patients," by Dr. Jollis, M.D., Eric D. Peterson, M.D., M.P.H., Charlotte L.
|
|
Nelson, M.S., and others, in the June 3, 1997, <em>Circulation</em> 95(11), pp. 2485-2491.</p>
|
|
<a name="head5"></a><h2>More women than men die in the hospital after a heart
|
|
attack, but experts disagree about the reasons for this disparity</h2>
|
|
<p>Women typically develop heart disease a decade later than men, but it continues to be the number
|
|
one killer of women in the United States. Although men are more apt to have heart attacks (acute
|
|
myocardial infarctions, AMIs) than women, women are more likely to die from them. </p><p>
|
|
|
|
Several studies have pointed to less access for women than men to revascularization procedures
|
|
and clot-busting (thrombolytic) therapy as an explanation for this difference in heart attack deaths.
|
|
Other studies have attributed the disparity to women's older age at the time of heart attack and
|
|
more coexisting medical problems, such as diabetes and hypertension. Two new studies supported
|
|
by the Agency for Health Care Policy and Research continue this debate and underscore the need
|
|
for more research on this issue. </p>
|
|
|
|
<p>The first study (Cardiac Arrhythmia Patient Outcomes Research Team [PORT], HS08362) finds
|
|
that even after accounting for differences between men and women in cardiac procedures, age,
|
|
and health factors, women were still 20 percent more likely than men to die in the hospital
|
|
following heart attack. In contrast, a second study (HS00060 and HS07360) concludes that
|
|
women's higher mortality rate is due to pulmonary congestion, older age, and greater number of
|
|
coexisting medical problems than men. </p><p>
|
|
|
|
<strong>Maynard, C., Every, N.R., Martin, J.S, and others (1997, June). "Association of gender
|
|
and survival in patients with acute myocardial infarction." <em>Archives of Internal Medicine</em>
|
|
157, pp. 1379-1384.</strong></p>
|
|
|
|
<p>This study of over 12,000 women and men with AMI treated in Seattle area hospitals between
|
|
1988 and 1994 shows that women were 20 percent more likely than men to die in the hospital.
|
|
Women were 8 years older than men; more often had a history of congestive heart failure,
|
|
hypertension, or diabetes mellitus; but less often had a history of AMI or coronary surgery.
|
|
Women were less apt than men to receive clot-busting therapy within 6 hours of hospital
|
|
admission (15 percent vs. 25 percent) and to undergo coronary angiography to diagnose heart
|
|
problems (46 percent vs. 63 percent), angioplasty (21 percent vs. 29 percent), or bypass surgery
|
|
(9 percent vs. 13 percent).</p> <p>
|
|
|
|
Even after adjusting for differences by sex in receipt of cardiac procedures, age, and health
|
|
factors, women's 20 percent greater risk of in-hospital death remained. </p>
|
|
|
|
<p>In addition, many of these older women (median age of 73 years) had long delay times from
|
|
symptom onset to hospital arrival and significant coexisting illnesses that decrease the benefits and
|
|
increase the risk of complications from thrombolytic therapy or revascularization. Consequently,
|
|
many of the women probably were not suitable candidates for these cardiac procedures, explain
|
|
University of Washington researchers who conducted the study. They also found that after
|
|
adjusting for age, survival after hospital discharge was similar for men and women.</p><p>
|
|
|
|
<strong>Coronado, B.E., Griffith, J.L., Beshansky, J.R., and Selker, H.P. (1997, June). "Hospital
|
|
mortality in women and men with acute cardiac ischemia: A prospective multicenter
|
|
study." <em>Journal of the American College of Cardiology</em> 29, pp. 1490-1496. </strong></p>
|
|
|
|
<p>The difference in hospital mortality rates for women and men who suffer heart attacks (10 percent
|
|
for women vs. 7 percent for men) appears to be accounted for by women's higher degree of
|
|
pulmonary congestion when they arrive at the emergency department (ED), older age, and greater
|
|
incidence of coexisting medical conditions, according to researchers at the New England Medical
|
|
Center and Tufts University. Their findings contrast with other studies, including the study
|
|
described above, where differences between men and women persisted after controlling for these
|
|
and other clinical factors.</p> <p>
|
|
|
|
The researchers analyzed data from a prospective multicenter study involving 10,783 older
|
|
patients (nearly half were women) presenting to the ED with symptoms suggesting acute cardiac
|
|
ischemia (restricted blood flow to the heart). These included chest pain, dizziness, nausea,
|
|
vomiting, jaw pain, difficult or labored breathing, chest pressure, upper abdominal pain, and left
|
|
arm pain. </p>
|
|
|
|
<p>Women had more hypertension (55 percent vs. 46 percent) and diabetes (23 percent vs. 17
|
|
percent) than men but fewer previous AMIs (21 percent vs. 29 percent). Women who presented
|
|
with an AMI also had more extensive heart damage than men. Age, diabetes, presenting systolic
|
|
blood pressure, and radiographic evidence of heart failure significantly predicted death from acute
|
|
cardiac ischemia and heart attack. Once these factors were accounted for, the trend for higher
|
|
mortality noted in women was no longer present.</p>
|
|
|
|
<a name="head6"></a><h2>Beta-blockers reduce deaths from congestive heart
|
|
failure</h2>
|
|
<p>About 40,000 persons in the United States die from congestive heart failure (CHF) each year.
|
|
Angiotensin-converting enzyme inhibitors significantly reduce death among these patients and as a
|
|
result have become the standard therapy for this condition. Several other drugs have been tried
|
|
with inconclusive or less-effective results. However, a recent meta-analysis of several studies
|
|
shows that beta-blocker therapy reduces the overall odds of death by 31 percent in patients with
|
|
chronic CHF, with one death prevented per 35 patients treated. This therapy improves survival
|
|
most for progressive, nonsudden rather than sudden cardiac death, with use of the alpha- and
|
|
beta-blocking agent carvedilol; the improved survival is unrelated to the cause of heart failure,
|
|
according to the study, which was supported by the Agency for Health Care Policy and Research
|
|
(National Research Service Award training grant T32 HS00028).</p> <p>
|
|
|
|
Beta-blockers reduced nonsudden cardiac death by 42 percent and sudden cardiac death by 16
|
|
percent. This difference was most notable in the noncarvedilol trials, which demonstrated a 34
|
|
percent decrease in the odds of nonsudden cardiac death and a 4 percent increase in the odds of
|
|
sudden cardiac death. This suggests that beta-blockers are more likely to prevent or delay the
|
|
progression of CHF (to nonsudden death) than exert a primary antiarrhythmic effect (to prevent
|
|
sudden death), note Paul A. Heidenreich, M.D., and Tina T. Lee, M.D., of Stanford University,
|
|
and Barry M. Massie, M.D., of the University of California, San Francisco. </p>
|
|
|
|
<p>The researchers conducted a meta-analysis of 17 randomized clinical trials of beta-blockade
|
|
treatment in 3,039 patients with CHF from January 1995 through February 1997. Based on all 17
|
|
reports, beta-blockade therapy significantly reduced mortality (odds ratio, OR of 0.69; 1 is equal
|
|
odds). A trend toward greater treatment effect was noted for nonsudden cardiac death (OR, 0.58)
|
|
compared with sudden cardiac death (OR, 0.84). Similar reduced deaths (OR, 0.69) were
|
|
observed for patients with ischemic and nonischemic cardiomyopathy. The survival benefit was
|
|
greater for trials of the drug carvedilol (OR, 0.54) than for noncarvedilol drugs (OR, 0.82), but
|
|
the difference was not significant. The researchers point out, however, that most of the studies
|
|
followed patients for 1 year or less, so the effect of beta-blockers on long-term survival is less
|
|
clear.</p><p>
|
|
|
|
See "Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of
|
|
randomized clinical trials," by Drs. Heidenreich, Lee, and Massie, in the July 1997 <em>Journal of
|
|
the
|
|
American College of Cardiology</em> 30, pp. 27-30. </p>
|
|
<a name="head7"></a><h2>Cardiologists and internists disagree about the risks
|
|
associated with frequently performed cardiac
|
|
procedures</h2>
|
|
<p>Cardiac procedures such as cardiac catheterization, angioplasty, and bypass surgery carry some
|
|
risks of serious complications and death. In general, cardiologists see these procedures as less
|
|
risky than do internists, but their judgments are not always more accurate, concludes a study
|
|
supported in part by the Agency for Health Care Policy and Research (HS06274).</p> <p>
|
|
|
|
Under managed care arrangements, conflicts could arise between generalist gatekeepers, who
|
|
believe the invasive cardiac procedures are relatively more hazardous, and cardiologists, who
|
|
believe they are less risky. These conflicts could be difficult to settle because the evidence
|
|
available in the medical literature is insufficient to determine which group of physicians is right,
|
|
according to Roy M. Poses, M.D., and Wally R. Smith, M.D., of the Medical College of Virginia,
|
|
and their colleagues. The researchers based their findings on a survey of senior staff and
|
|
physician-trainees at two hospitals affiliated with a U.S. medical school and two hospitals
|
|
associated with a U.K. medical school.</p>
|
|
|
|
<p>Based on risk assessment of four cardiac procedures, cardiologists at the four hospitals
|
|
systematically judged the risks to be much lower than hospital internists. Cardiologists and
|
|
internists each judged the risks accurately about half the time. Cardiologists were more accurate in
|
|
their judgments of the rates of serious problems (morbidity) and death due to cardiac
|
|
catheterizations, but internists were more accurate in their judgments of rates of morbidity due to
|
|
Swan-Ganz catheterization and angioplasty. There were no clear differences between
|
|
cardiologists' and internists judgments of death due to Swan-Ganz catheterization, angioplasty,
|
|
or bypass surgery or morbidity due to bypass surgery.</p><p>
|
|
|
|
Cardiologists' personal experiences with these procedures may encompass many more good
|
|
outcomes than bad ones. Internists, however, may only become personally involved in such
|
|
procedures when they are called about bad outcomes. On the other hand, physicians may look
|
|
more favorably on the treatments they use than on treatments used by other physicians. Finally,
|
|
disagreements about the risks of procedures may arise from a paucity of published data on the
|
|
risks of cardiac catheterization or from an abundance of confusing, contradictory data on
|
|
angioplasty and bypass surgery. </p>
|
|
|
|
<p>See "Physicians' judgments of the risks of cardiac procedures: Differences between cardiologists
|
|
and other internists," by Dr. Poses, Donna K. McClish, Ph.D., Dr. Smith, and others, in <em>Medical
|
|
Care</em> 35(6), pp. 603-617.</p>
|
|
<p class="size2"><a href=".">Return to Contents</a></p>
|
|
|
|
<a name="head8"></a><h1>Medical Effectiveness/Outcomes Research</h1>
|
|
<a name="head9"></a><h2>Low Birthweight PORT publishes recent findings</h2>
|
|
<p>Conditions ranging from maternal low weight and substance abuse to vaginal infections and
|
|
sexually transmitted diseases have been linked to low birthweight (LBW) and other neonatal
|
|
problems. The goals of the Patient Outcomes Research Team (PORT) on the Prevention of Low
|
|
Birthweight in Minority and High-Risk Women are to better define the risk factors associated
|
|
with LBW, determine its causes, and evaluate the effectiveness of strategies aimed at the
|
|
prevention of LBW. The PORT is led by Robert L. Goldenberg, M.D., of the University of
|
|
Alabama at Birmingham and supported by the Agency for Health Care Policy and Research
|
|
(PORT contract 290-92-0055).</p><p>
|
|
|
|
The PORT researchers recently published the following three articles. One, the cost of caring for
|
|
infants who contract congenital syphilis from mothers with syphilis is more than three times that
|
|
of infants without this problem. Two, high blood levels of alkaline phosphatase at 26 weeks'
|
|
gestation and changes in activities of this enzyme between 19 and 26 weeks' gestation are both
|
|
associated with a three-fold increase in the risk for preterm delivery. And three, vaginal irrigation
|
|
with the medical disinfectant chlorhexidine during active labor or before planned cesarean section
|
|
is not effective in preventing maternal infection shortly before or after childbirth. The articles are
|
|
summarized below.</p>
|
|
|
|
<p><strong>Bateman, D.A., Phibbs, C.S., Joyce, T., and Heagarty, M.C. (1997, May). "The hospital
|
|
cost of congenital syphilis." <em>The Journal of Pediatrics</em> 130(5), pp. 752-758.</strong></p><p>
|
|
|
|
Congenital syphilis has risen sharply in the United States, reaching a peak in 1989 to 1991, with
|
|
most cases occurring in urban minority groups. Infants contract congenital syphilis from their
|
|
mothers, either prenatally or at birth. The Centers for Disease Control and Prevention (CDC)
|
|
guidelines for treatment of congenital syphilis require that newborns suspected of having this
|
|
problem be given parenteral penicillin therapy for at least 10 days following delivery, usually while
|
|
hospitalized. The unadjusted mean cost of caring for these infants ($11,031) is more than three
|
|
times that of caring for infants without syphilis, according to this study. </p>
|
|
|
|
<p>The researchers used Medicaid reimbursement data to compare the cost of caring for 114
|
|
newborn infants treated for confirmed or presumptive congenital syphilis with the cost of caring
|
|
for 2,906 infants without syphilis at Harlem Hospital in New York City in 1989. </p> <p>
|
|
|
|
After controlling for maternal behaviors and newborn risk factors that might influence length of
|
|
neonatal hospitalization, infants with syphilis had an additional hospital stay of 7.5 days and an
|
|
additional cost of $4,691 above mean study population values (7.13 days, $3,473). A maternal
|
|
history of injection drug use added another 7.7 days at a cost of $3,946. Based on the number of
|
|
reported cases of congenital syphilis from 1991 to 1994, the average national cost per year of
|
|
treating these infants is about $18.4 million (1995 dollars). </p>
|
|
|
|
<p>Congenital syphilis is a preventable disease. Preventing cases of maternal syphilis and treating
|
|
pregnant women for syphilis would reduce the number of congenital cases needing treatment. The
|
|
additional cost of treating syphilis during pregnancy—for repeated blood tests, one or two
|
|
additional doctor visits, and penicillin—would add several hundred dollars to the cost of a
|
|
routine
|
|
prenatal care program. Given the higher rate of intrauterine cocaine exposure among neonates
|
|
with congenital syphilis in this study (70 percent), as well as the cost of this exposure, programs
|
|
that combine prenatal care with maternal treatment for substance use and other high-risk
|
|
behaviors may be more effective and yield additional savings, conclude the researchers.</p><p>
|
|
|
|
<strong>Goldenberg, R.L., Tamura, T., DuBard, M., and others (1997). "Plasma alkaline
|
|
phosphatase and pregnancy outcome." <em>Journal of Maternal-Fetal Medicine</em> 6, pp.
|
|
140-145.</strong></p>
|
|
|
|
<p>Alkaline phosphatase is an enzyme found in tissues throughout the body, including the placenta,
|
|
and increases in plasma activity occur as pregnancy approaches term. Several studies have
|
|
suggested a relationship between elevated alkaline phosphatase activity and low birthweight,
|
|
preeclampsia, prematurity, and placental insufficiency. This study finds that high plasma alkaline
|
|
phosphatase activity at about 26 weeks' gestation and changes in alkaline phosphatase activity
|
|
between 19 and 26 weeks' gestation are both associated with about a three-fold increased risk for
|
|
preterm delivery. This finding remains significant after adjusting for a number of maternal
|
|
characteristics and for plasma copper, folate, and albumin, substances that are associated with
|
|
alkaline phosphatase activity.</p><p>
|
|
|
|
Most significant risk factors for preterm delivery predict an odds ratio (OR) of 2.0 or less. This
|
|
study found that alkaline phosphatase activity at 26 weeks' gestation had an OR of 5.0 for
|
|
delivery at 32 weeks or earlier, suggesting that it is a relatively powerful predictor of early
|
|
preterm delivery. The researchers hypothesize that infection of the chorioamnion, the outermost
|
|
embryonic membrane that gives rise to the placenta, or disruption of the interface between the
|
|
embryonic membrane and uterine lining by some other mechanism, may increase the production or
|
|
release of placental alkaline phosphatase into the circulation. The researchers caution, however,
|
|
that at this time there is insufficient information to recommend the routine use of tests for
|
|
measuring plasma alkaline phosphatase for the prediction of preterm delivery and low birthweight.
|
|
</p>
|
|
|
|
<p><strong>Rouse, D.J., Hauth, J.C., Andrews, W.W., and others (1997). "Chlorhexidine vaginal
|
|
irrigation for the prevention of peripartal infection: A placebo-controlled randomized
|
|
clinical trial." <em>American Journal of Obstetrics & Gynecology</em> 176, pp. 617-622.</strong></p><p>
|
|
|
|
Chlorhexidine is a widely used medical disinfectant with antimicrobial activity against a broad
|
|
spectrum of vaginal bacteria. It has been shown to reduce neonatal morbidity associated with
|
|
group B streptococci. This study tested whether a single vaginal irrigation with dilute
|
|
chlorhexidine solution administered during active labor or before cesarean delivery would be
|
|
effective in preventing maternal infection during the last month of pregnancy or the first 3 months
|
|
after delivery. The researchers administered chlorhexidine during active labor or before planned
|
|
cesarean delivery to 508 women and sterile water placebo to 516 women. </p>
|
|
|
|
<p>Rates of infection (intrapartum chorioamnionitis and postpartum endometritis) did not differ
|
|
significantly between the groups, with 10 percent of women receiving chlorhexidine having
|
|
infections versus 13 percent of women who received the sterile water. Neonatal outcomes,
|
|
including sepsis rates of 0.4 percent, were equivalent for both groups. Thus, vaginal irrigation
|
|
with dilute chlorhexidine solution about 4.5 hours before delivery did not prevent maternal
|
|
peripartal infection. Either the solution lacked activity against the bacteria responsible for the
|
|
infections, it was not given early enough or should have been repeated, or the irrigant was not
|
|
adequately dispersed throughout the vagina for other reasons, conclude the researchers. </p>
|
|
<a name="head10"></a><h2>Most people take more than 30 days following
|
|
pneumonia to be symptom-free</h2>
|
|
<p>For most persons with community-acquired pneumonia (CAP), it takes at least 30 days for the
|
|
symptoms of cough, chest pain, labored breathing (dyspnea), and fatigue to resolve. When
|
|
symptoms take longer to disappear, individuals generally make additional visits to the doctor,
|
|
according to a study by the Pneumonia Patient Outcomes Research Team (PORT), which is
|
|
supported by the Agency for Health Care Policy and Research (HS06468) and led by Wishwa N.
|
|
Kapoor, M.D., M.P.H., of the University of Pittsburgh.</p><p>
|
|
|
|
The researchers studied 576 adults with clinical and x-ray evidence of pneumonia who were
|
|
judged to be at low risk of dying. They documented the presence and severity of five symptoms
|
|
(cough, fatigue, dyspnea, sputum, and chest pain) through questionnaires administered to the
|
|
patients at diagnosis and at 1 week, 1 month, and 3 months later. The researchers also determined
|
|
the reason for and number of outpatient physician visits during that time.</p>
|
|
|
|
<p>Physical health had declined significantly at diagnosis but improved during the subsequent
|
|
followup. With the exception of pleuritic chest pain, symptoms continued to be a problem at 30
|
|
days, and some symptoms continued to be bothersome at 90 days. For instance, fatigue was
|
|
reported by 51 percent of patients at day 30 with 20 percent still reporting moderate to severe
|
|
fatigue at day 90; 32 percent of patients reported cough and 27 percent reported sputum 90 days
|
|
after diagnosis.</p> <p>
|
|
|
|
Patients with elevated symptom scores at 1 week or 1 month after diagnosis were significantly
|
|
more apt to report pneumonia-related outpatient care visits 1 month and 3 months later. For
|
|
instance, 43 percent of patients with the fewest symptoms a week after diagnosis subsequently
|
|
reported pneumonia-related outpatient visits by day 30 compared with 72 percent of patients with
|
|
the most symptoms. This relationship remained significant even after adjusting for the patients
|
|
age, site of care, coexisting conditions, and severity of illness. Physicians should inform patients
|
|
with pneumonia of the possibility that their symptoms may not resolve for quite some time. It is
|
|
possible that if physicians better informed patients, the rate of pneumonia-related outpatient visits
|
|
might decrease, conclude the researchers.</p>
|
|
|
|
<p>See "Measuring symptomatic and functional recovery in patients with community-acquired
|
|
pneumonia," by Joshua P. Metlay, M.D., Ph.D., Michael J. Fine, M.D., M.Sc., Richard Schulz,
|
|
Ph.D., and others in the July 1997 <em>Journal of General Internal Medicine</em> 12, pp. 423-430.</p>
|
|
|
|
<p class="size2"><a href=".">Return to Contents</a><br />
|
|
<a href="ra2.htm">Proceed to Next Section</a></p>
|
|
|
|
<div class="footnote">
|
|
<p> The information on this page is archived and provided for reference purposes only.</p></div>
|
|
<p> </p>
|
|
</div>
|
|
</td>
|
|
</tr>
|
|
</table>
|
|
<!-- End of Center Content section -->
|
|
</td>
|
|
</tr>
|
|
</table>
|
|
</div>
|
|
<!-- End of Content Body -->
|
|
<!-- Footer graphic 1.2-->
|
|
<table cellspacing="0" cellpadding="0" border="0" width="100%">
|
|
<tr>
|
|
<td width="125" background="/images/bottom_ahrq_bkg.jpg"><img src="/images/bottom_ahrq_1.jpg" width="125" alt="AHRQ" /></td>
|
|
<td width="100%" background="/images/bottom_ahrq_bkg.jpg" ><img src="/images/bottom_ahrq_bkg.jpg" width="10" height="34" alt="" /></td>
|
|
|
|
<td width="310" background="/images/bottom_ahrq_bkg.jpg"><img src="/images/bottom_ahrq_2.gif" alt="Advancing Excellence in Health Care" width="310" height="34" /></td>
|
|
</tr>
|
|
</table>
|
|
<!-- Footer links section -->
|
|
<div id="banner_Footer2"><p> <a href="https://www.ahrq.gov/">AHRQ Home</a> | <a href="https://info.ahrq.gov" class="footer_navlink">Questions?</a> | <a href="https://www.ahrq.gov/contact/index.html" class="footer_navlink">Contact AHRQ</a> | <a href="https://www.ahrq.gov/sitemap.html" class="footer_navlink">Site Map</a> | <a href="https://www.ahrq.gov/policy/electronic/accessibility/index.html" class="footer_navlink">Accessibility</a> | <a href="https://www.ahrq.gov/policy/electronic/privacy/index.html" class="footer_navlink">Privacy
|
|
Policy</a> | <a href="https://www.ahrq.gov/policy/foia/index.html" class="footer_navlink">Freedom of Information Act</a> | <a href="https://www.ahrq.gov/policy/electronic/disclaimers/index.html" class="footer_navlink">Disclaimers</a> | <a href="http://www.hhs.gov/open/recordsandreports/plainwritingact/index.html" class="footer_navlink">Plain Writing Act</a> <br />
|
|
|
|
<a href="http://www.hhs.gov" class="footer_navlink">U.S. Department of Health & Human Services</a> | <a href="http://www.whitehouse.gov" class="footer_navlink">The White House</a> | <a href="http://www.usa.gov" class="footer_navlink">USA.gov: The U.S. Government's Official Web Portal</a></p>
|
|
</div>
|
|
<div id="banner_Footeraddress"><p>Agency for Healthcare Research and Quality <img src="/images/bottom_dot.gif" alt="" /> 5600 Fishers Lane Rockville, MD 20857 <img src="/images/bottom_dot.gif" alt="" /> Telephone: (301) 427-1364</p></div>
|
|
|
|
<!-- End of Footer links section -->
|
|
</body>
|
|
</html> |